51 related articles for article (PubMed ID: 26272024)
1. The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor.
Casa AJ; Hochbaum D; Sreekumar S; Oesterreich S; Lee AV
Mol Cell Endocrinol; 2015 Nov; 415():76-86. PubMed ID: 26272024
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus.
Valley CC; Métivier R; Solodin NM; Fowler AM; Mashek MT; Hill L; Alarid ET
Mol Cell Biol; 2005 Jul; 25(13):5417-28. PubMed ID: 15964799
[TBL] [Abstract][Full Text] [Related]
3. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
Hu B; Hu J
Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
[TBL] [Abstract][Full Text] [Related]
4. Selective mutations in estrogen receptor alpha D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms.
Burns KA; Li Y; Arao Y; Petrovich RM; Korach KS
J Biol Chem; 2011 Apr; 286(14):12640-9. PubMed ID: 21285458
[TBL] [Abstract][Full Text] [Related]
5. Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.
Kapara A; Findlay Paterson KA; Brunton VG; Graham D; Zagnoni M; Faulds K
Anal Chem; 2021 Apr; 93(14):5862-5871. PubMed ID: 33797884
[TBL] [Abstract][Full Text] [Related]
6. Activation of estrogen receptor-alpha by the anion nitrite.
Veselik DJ; Divekar S; Dakshanamurthy S; Storchan GB; Turner JM; Graham KL; Huang L; Stoica A; Martin MB
Cancer Res; 2008 May; 68(10):3950-8. PubMed ID: 18483281
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
Wang Y; Min J; Deng X; Feng T; Hu H; Guo X; Cheng Y; Xie B; Yang Y; Chen CC; Guo RT; Dong C; Zhou HB
Acta Pharm Sin B; 2023 Dec; 13(12):4963-4982. PubMed ID: 38045063
[TBL] [Abstract][Full Text] [Related]
8. Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.
Liang J; Blake R; Chang J; Friedman LS; Goodacre S; Hartman S; Ingalla ER; Kiefer JR; Kleinheinz T; Labadie S; Li J; Lai KW; Liao J; Mody V; McLean N; Metcalfe C; Nannini M; Otwine D; Ran Y; Ray N; Roussel F; Sambrone A; Sampath D; Vinogradova M; Wai J; Wang T; Yeap K; Young A; Zbieg J; Zhang B; Zheng X; Zhong Y; Wang X
ACS Med Chem Lett; 2020 Jun; 11(6):1342-1347. PubMed ID: 32551022
[TBL] [Abstract][Full Text] [Related]
9. Electrochemistry detection of estrogenic effect: Regulation of de novo purine synthesis and catabolism by gibberellin and fulvestrant.
Wang Y; Zhao S; Wang S; Zhang J; Zhao Y; Ye C; Zhao Z; Li J; Shen H; Wu D
Bioelectrochemistry; 2024 Apr; 156():108634. PubMed ID: 38160510
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Hao Y; Lin PL; Xie J; Li N; Koo V; Ohashi E; Wu EQ; Rogerio J
J Comp Eff Res; 2015 Aug; 4(4):315-26. PubMed ID: 26274793
[TBL] [Abstract][Full Text] [Related]
11. Progesterone receptor-estrogen receptor crosstalk: a novel insight.
Thomas C; Gustafsson JÅ
Trends Endocrinol Metab; 2015 Sep; 26(9):453-4. PubMed ID: 26277479
[TBL] [Abstract][Full Text] [Related]
12. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges.
Boisen MM; Andersen CL; Sreekumar S; Stern AM; Oesterreich S
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():322-33. PubMed ID: 26276546
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Chan HJ; Petrossian K; Chen S
J Steroid Biochem Mol Biol; 2016 Jul; 161():73-83. PubMed ID: 26277097
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha and beta in health and disease.
Jia M; Dahlman-Wright K; Gustafsson JÅ
Best Pract Res Clin Endocrinol Metab; 2015 Aug; 29(4):557-68. PubMed ID: 26303083
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen receptors interact with the α-catalytic subunit of AMP-activated protein kinase.
Lipovka Y; Chen H; Vagner J; Price TJ; Tsao TS; Konhilas JP
Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26374855
[TBL] [Abstract][Full Text] [Related]
16. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.
McFall T; Patki M; Rosati R; Ratnam M
Oncotarget; 2015 Oct; 6(32):33146-64. PubMed ID: 26356672
[TBL] [Abstract][Full Text] [Related]
17. [Fulvestrant (Faslodex®) for hormone sensitive breast cancer. A review].
Nagykálnai T; Landherr L; Laczó I; Pikó B
Magy Onkol; 2015 Sep; 59(3):251-7. PubMed ID: 26339914
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition.
Katz TA; Liao SG; Palmieri VJ; Dearth RK; Pathiraja TN; Huo Z; Shaw P; Small S; Davidson NE; Peters DG; Tseng GC; Oesterreich S; Lee AV
Cancer Prev Res (Phila); 2015 Oct; 8(10):1000-9. PubMed ID: 26290394
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
20. ERβ expression and breast cancer risk prediction for women with atypias.
Hieken TJ; Carter JM; Hawse JR; Hoskin TL; Bois M; Frost M; Hartmann LC; Radisky DC; Visscher DW; Degnim AC
Cancer Prev Res (Phila); 2015 Nov; 8(11):1084-92. PubMed ID: 26276747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
